石四藥集團(02005.HK)2022年度歸母淨利潤升43%至11.23億港元 銷售收入再創歷史新高
格隆匯3月28日丨石四藥集團(02005.HK)公佈2022年度業績,全年實現銷售收入64.34億港元,同比增長約20%,同期毛利率55.4%,同比下降3.8個百分點,毛利率下降主要原因是原料藥佔收入比例的增加,但也帶來銷售費用的下降。實現公司股權持有人應占溢利11.23億港元,同比增長約43%。每股基本盈利0.3761港元,宣派末期股息每股0.08港元,全年合共派息每股0.14港元。
2022年,針對新冠疫情反覆波動和國家藥品集採改革深層遞進,集團聚焦國內、國際市場需求,積極克服困難,高效統籌市場資源配置,加大優勢製劑、重點製劑品種及大宗原料藥和藥包材的市場拓展,不斷優化產品結構,突出特色新品營銷,市場份額、銷售規模取得新進展,整體經營持續穩定向好,集團銷售收入再創歷史新高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.